A study found that routine histopathology reports on melanoma patients can help predict which patients are most likely to develop immune-related adverse events while taking immune checkpoint inhibitors. The study evaluated 511 patients and found that the presence of lymphovascular invasion and NRAS mutation were associated with increased odds of developing all-grade immune-related adverse events. However, no histopathological features were found to predict high-grade adverse events. The study did not make any practice recommendations and had limitations, including being retrospective and potentially not generalizable due to institutional variation in histopathology report interpretation. The study was conducted by researchers from Brigham and Women’s Hospital and was supported by Harvard Medical School. Some authors disclosed consulting and honoraria fees from various pharmaceutical companies.
Source link
ICIs in Melanoma: Predicting Immune-related Adverse Events
